Search

Your search keyword '"Lu, Jia-cheng"' showing total 117 results
Start Over Author "Lu, Jia-cheng"
117 results on '"Lu, Jia-cheng"'

1. Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors

Author

Zhang, Dao-Han, Liang, Chen, Hu, Shu-Yang, Huang, Xiao-Yong, Yu, Lei, Meng, Xian-Long, Guo, Xiao-Jun, Zeng, Hai-Ying, Chen, Zhen, Zhang, Lv, Pei, Yan-Zi, Ye, Mu, Cai, Jia-Bin, Huang, Pei-Xin, Shi, Ying-Hong, Ke, Ai-Wu, Chen, Yi, Ji, Yuan, Shi, Yujiang Geno, Zhou, Jian, Fan, Jia, Yang, Guo-Huan, Sun, Qi-Man, Shi, Guo-Ming, and Lu, Jia-Cheng

Published
2024
Full Text
View/download PDF

3. Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma

Author

Lu, Jia-Cheng, Wu, Lei-Lei, Sun, Yi-Ning, Huang, Xiao-Yong, Gao, Chao, Guo, Xiao-Jun, Zeng, Hai-Ying, Qu, Xu-Dong, Chen, Yi, Wu, Dong, Pei, Yan-Zi, Meng, Xian-Long, Zheng, Yi-Min, Liang, Chen, Zhang, Peng-Fei, Cai, Jia-Bin, Ding, Zhen-Bin, Yang, Guo-Huan, Ren, Ning, Huang, Cheng, Wang, Xiao-Ying, Gao, Qiang, Sun, Qi-Man, Shi, Ying-Hong, Qiu, Shuang-Jian, Ke, Ai-Wu, Shi, Guo-Ming, Zhou, Jian, Sun, Yi-Di, and Fan, Jia

Published
2024
Full Text
View/download PDF

4. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Author

Shi, Guo-Ming, Huang, Xiao-Yong, Wu, Dong, Sun, Hui-Chuan, Liang, Fei, Ji, Yuan, Chen, Yi, Yang, Guo-Huan, Lu, Jia-Cheng, Meng, Xian-Long, Wang, Xin-Ying, Sun, Lei, Ge, Ning-Ling, Huang, Xiao-Wu, Qiu, Shuang-Jian, Yang, Xin-Rong, Gao, Qiang, He, Yi-Feng, Xu, Yang, Sun, Jian, Ren, Zheng-Gang, Fan, Jia, and Zhou, Jian

Published
2023
Full Text
View/download PDF

13. Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.

Author

Lu, Jia-Cheng, Wu, Lei-Lei, Sun, Yi-Ning, Huang, Xiao-Yong, Gao, Chao, Guo, Xiao-Jun, Zeng, Hai-Ying, Qu, Xu-Dong, Chen, Yi, Wu, Dong, Pei, Yan-Zi, Meng, Xian-Long, Zheng, Yi-Min, Liang, Chen, Zhang, Peng-Fei, Cai, Jia-Bin, Ding, Zhen-Bin, Yang, Guo-Huan, Ren, Ning, and Huang, Cheng

Subjects
CHOLANGIOCARCINOMA, T cells, IMMUNITY, CD8 antigen, TUMOR microenvironment, OXALIPLATIN
Abstract

Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR profiles of 18 tumor tissues pre- and post- therapy of gemcitabine plus oxaliplatin, in combination with lenvatinib and anti-PD1 antibody for intrahepatic cholangiocarcinoma. We find that high CD8 GZMB+ and CD8 proliferating proportions and a low Macro CD5L+ proportion predict good response to the therapy. In patients with a poor response, the CD8 GZMB+ and CD8 proliferating proportions are increased, but the CD8 GZMK+ proportion is decreased after the therapy. Transition of CD8 proliferating and CD8 GZMB+ to CD8 GZMK+ facilitates good response to the therapy, while Macro CD5L+–CD8 GZMB+ crosstalk impairs the response by increasing CTLA4 in CD8 GZMB+. Anti-CTLA4 antibody reverses resistance of the therapy in intrahepatic cholangiocarcinoma. Our data provide a resource for predicting response of the combination therapy and highlight the importance of CD8+T-cell status conversion and exhaustion induced by Macro CD5L+ in influencing the response, suggesting future avenues for cancer treatment optimization. The role of the tumor microenvironment in immunotherapy response in intrahepatic cholangiocarcinoma remains unclear. Here, single cell RNA and TCR sequencing of samples before and after immunotherapy highlights the role of CD8 T-cell status conversion and exhaustion induced by Macro CD5L+ in treatment response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Application of a Single-Cell-RNA-Based Biological-Plausible Graph Neural Network in Diagnosis of Primary Liver Tumours

Author

Zhang, Dao-Han, primary, Liang, Chen, additional, Huang, Xiao-Yong, additional, Yu, Lei, additional, Meng, Xianlong, additional, Guo, Xiao-Jun, additional, Zeng, Hai-Ying, additional, Chen, Zhen, additional, Zhang, Lv, additional, Pei, Yanzi, additional, Hu, Shu-Yang, additional, Ye, Mu, additional, Cai, Jiabin, additional, Huang, Pei-Xin, additional, Shi, Ying-Hong, additional, Ke, Aiwu, additional, Chen, Yi, additional, Ji, Yuan, additional, Shi, Yujiang Geno, additional, Zhou, Jian, additional, Fan, Jia, additional, Yang, Guo-Huang, additional, Sun, Qi-Man, additional, Shi, Guo-Ming, additional, and Lu, Jia-Cheng, additional

Published
2023
Full Text
View/download PDF

18. The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion

Author

Meng, Xian-Long, primary, Lu, Jia-Cheng, additional, Zeng, Hai-Ying, additional, Chen, Zhen, additional, Guo, Xiao-Jun, additional, Gao, Chao, additional, Pei, Yan-Zi, additional, Hu, Shu-Yang, additional, Ye, Mu, additional, Sun, Qi-Man, additional, Yang, Guo-Huang, additional, Cai, Jia-Bin, additional, Huang, Pei-Xin, additional, Yv, Lei, additional, Zhang, Lv, additional, Shi, Ying-Hong, additional, Ke, Ai-Wu, additional, Zhou, Jian, additional, Fan, Jia, additional, Chen, Yi, additional, Huang, Xiao-Yong, additional, and Shi, Guo-Ming, additional

Published
2022
Full Text
View/download PDF

22. Molecular Features and Clinical Implications of Perineural Invasion in Intrahepatic Cholangiocarcinoma

Author

Meng, Xianlong, primary, Lu, Jia-Cheng, additional, Zeng, Haiying, additional, Chen, Zhen, additional, Zhang, Lv, additional, Guo, Xiaojun, additional, Gao, Chao, additional, Pei, Yanzi, additional, Hu, Shuyang, additional, Ye, Mu, additional, Sun, Qiman, additional, Yang, Guohuang, additional, Cai, Jiabin, additional, Shi, Ying-Hong, additional, Ke, Aiwu, additional, Zhou, Jian, additional, Fan, Jia, additional, Huang, Xiaoyong, additional, and Shi, Guo-Ming, additional

Published
2022
Full Text
View/download PDF

24. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma

Author

Guo, Xiao-Jun, primary, Lu, Jia-Cheng, additional, Zeng, Hai-Ying, additional, Zhou, Rong, additional, Sun, Qi-Man, additional, Yang, Guo-Huan, additional, Pei, Yan-Zi, additional, Meng, Xian-Long, additional, Shen, Ying-Hao, additional, Zhang, Peng-Fei, additional, Cai, Jia-Bin, additional, Huang, Pei-Xin, additional, Ke, Ai-Wu, additional, Shi, Ying-Hong, additional, Zhou, Jian, additional, Fan, Jia, additional, Chen, Yi, additional, Yang, Liu-Xiao, additional, Shi, Guo-Ming, additional, and Huang, Xiao-Yong, additional

Published
2021
Full Text
View/download PDF

27. Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.

Author

Jian, Zhou, primary, Fan, Jia, additional, Shi, Guo-Ming, additional, Huang, Xiao-Yong, additional, Wu, Dong, additional, Yang, Guo-Huan, additional, Ji, Yuan, additional, Chen, Yi, additional, Liang, Fei, additional, Lu, Jia-Cheng, additional, Ge, Ning-Ling, additional, Sun, Hui-Chuan, additional, Huang, Xiao-Wu, additional, Qiu, Shuang-Jian, additional, He, Yi-Feng, additional, Yang, Xin-Rong, additional, Xu, Yang, additional, Gao, Qiang, additional, and Sun, Jian, additional

Published
2021
Full Text
View/download PDF

28. Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.

Author

Jian, Zhou, primary, Fan, Jia, additional, Shi, Guo-Ming, additional, Huang, Xiao-Yong, additional, Wu, Dong, additional, Liang, Fei, additional, Yang, Guo-Huan, additional, Lu, Jia-Cheng, additional, Chen, Yi, additional, Ge, Ning-Ling, additional, Ji, Yuan, additional, Hou, YY, additional, Sun, Hui-Chuan, additional, Qiu, Shuang-Jian, additional, Ye, Qing-Hai, additional, Huang, Xiao-Wu, additional, Shi, Ying-Hong, additional, Gao, Qiang, additional, Yang, Xin-Rong, additional, and Wang, Xiao-Ying, additional

Published
2021
Full Text
View/download PDF

29. Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.

Author

Shi, Guo-Ming, primary, Jian, Zhou, additional, Fan, Jia, additional, Huang, Xiao-Yong, additional, Wu, Dong, additional, Liang, Fei, additional, Lu, Jia-Cheng, additional, Yang, Guo-Huan, additional, Chen, Yi, additional, Ge, Ning-Ling, additional, Ji, Yuan, additional, Hou, YY, additional, Sun, Hui-Chuan, additional, Qiu, Shuang-Jian, additional, Ye, Qing-Hai, additional, Huang, Xiao-Wu, additional, Shi, Ying-Hong, additional, Gao, Qiang, additional, Yang, Xin-Rong, additional, and Wang, Zheng, additional

Published
2021
Full Text
View/download PDF

30. Additional file 5 of Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

Author

Huang, Xiao-Yong, Zhang, Peng-Fei, Chuan-Yuan Wei, Peng, Rui, Lu, Jia-Cheng, Gao, Chao, Cai, Jia-Bing, Yang, Xuan, Fan, Jia, Ke, Ai-Wu, Zhou, Jian, and Shi, Guo-Ming

Abstract

Additional file 5: Figure S1. a. The agreement between RNA-seq and qRT-PCR results; b. A negative relationship between CD8 and circMET; c. The relationship between CD4+ and CD8+ T cells in HCC tissues and the overall survival and cumulative recurrence of HCC patients was analyzed in 209 HCC patients. Figure S2. a. The expression of miR-30a/b/c/d/e-5p in HepG2 and HCCLM3 cells was determined by qRT-PCR; b. The expression of snail in HCC cells interfered with miR-30a/b/c/d/e-5p, (here we only showed miR-30b/c/d -5p); c. The chip peaks over chromosomes in snail Chip-seq; d The repertoire of snail-binding sites in HCC cell lines; Figure S3. The expression of 27 genes from the TCGA. Figure S4. a. The luciferase activity of DPP4 was upregulated in cells cotransfected with the Snail DDP4-promoter and 21,975 + TK/ 21,976 + TK; b. The luciferase activity of PDGFB after cotransfection of Snail and PDGFB vectors; c. The luciferase activity of CSPP1 after cotransfection of Snail and CSPP1 vectors; d. Snail interacts with distant sites 140,810 and 96,828 of DPP4 as enhancer elements to upregulate the DPP4 expression. Figure S5. a. The DPP4 level in Hep1–6 cells interfered with si-miR-30b-5p or si-miR-30c-5p or si-miR-30d-5p; b. Chemokine chips were used to determine the differences in chemokines between the sera of mice implanted with Hep-1-6-snail and the sera of mice implanted with Hep-1-6-shmiR-30s cells; c. Images of Hep1–6 tumors from each group and Tumor growth curves of Hep-1-6 tumors from each group(n = 3); d. Images of Hep1–6-circMET and Hep1–6-snail tumors from each group and Tumor growth curves of Hep-1-6-circMET and Hep1–6-snail tumors from each group (n = 3).

Published
2020
Full Text
View/download PDF

36. Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti–Programmed Death 1 Immunotherapy for Recurrent Liver Tumors

Author

Shi, Guo‐Ming, primary, Wang, Jiping, additional, Huang, Xiao‐Wu, additional, Huang, Xiao‐Yong, additional, He, Yi‐Feng, additional, Ji, Yuan, additional, Chen, Yi, additional, Wu, Dong, additional, Lu, Jia‐Cheng, additional, Sun, Qi‐Man, additional, Liu, Wei‐Ren, additional, Wang, Ting, additional, Yang, Liu‐Xiao, additional, Hou, Ying‐Yong, additional, Shi, Ying‐Hong, additional, Sun, Jian, additional, Xiao, Yong‐Sheng, additional, Wang, Zheng, additional, Fan, Jia, additional, Bertagnolli, Monica M., additional, and Zhou, Jian, additional

Published
2020
Full Text
View/download PDF

37. Additional file 5: of Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma

Author

Peng, Rui, Zhang, Peng-Fei, Yang, Xuan, Chuan-Yuan Wei, Huang, Xiao-Yong, Cai, Jia-Bin, Lu, Jia-Cheng, Gao, Chao, Sun, Hai-Xiang, Gao, Qiang, Dou-Sheng Bai, Shi, Guo-Ming, Ke, Ai-Wu, and Fan, Jia

Subjects
fungi
Abstract

Figure S3. The AHNAK expression in HCCLM3 and HCCLM3-siAHNAK cells. Western blot showed that the expression of AHNAK after transfecting the short interfering RNA to HCCLM3. (PDF 152 kb)

Published
2019
Full Text
View/download PDF

38. Additional file 7: of Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma

Author

Peng, Rui, Zhang, Peng-Fei, Yang, Xuan, Chuan-Yuan Wei, Huang, Xiao-Yong, Cai, Jia-Bin, Lu, Jia-Cheng, Gao, Chao, Sun, Hai-Xiang, Gao, Qiang, Dou-Sheng Bai, Shi, Guo-Ming, Ke, Ai-Wu, and Fan, Jia

Abstract

Table S2. SILAC of differential proteins in HepG2-RNF38 and HepG2-vector (Up-regulated) (DOCX 43 kb)

Published
2019
Full Text
View/download PDF

40. Additional file 3: of Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma

Author

Peng, Rui, Zhang, Peng-Fei, Yang, Xuan, Chuan-Yuan Wei, Huang, Xiao-Yong, Cai, Jia-Bin, Lu, Jia-Cheng, Gao, Chao, Sun, Hai-Xiang, Gao, Qiang, Dou-Sheng Bai, Shi, Guo-Ming, Ke, Ai-Wu, and Fan, Jia

Abstract

Figure S1. Analysis RNF38 mRNA level in gastrointestinal tumor vs. normal tissues. A-D. RNF38 mRNA level was up-regulated in colon cancer, gastric cancer, and liver cancer, compared to normal tissues (All data retrieved from www.oncomine.org ). (PDF 114 kb)

Published
2019
Full Text
View/download PDF

44. Additional file 6: of Circular RNA circTRIM33–12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression

Author

Zhang, Peng-Fei, Chuan-Yuan Wei, Huang, Xiao-Yong, Peng, Rui, Yang, Xuan, Lu, Jia-Cheng, Zhang, Chi, Gao, Chao, Cai, Jia-Bin, Gao, Ping-Ting, Gao, Dong-Mei, Shi, Guo-Ming, Ke, Ai-Wu, and Fan, Jia

Subjects
neoplasms, digestive system diseases
Abstract

Figure S1. circTRIM33–12 expression in HCC cells. Figure S2. circTRIM33–12 regulated the progression of HCC cells in vitro. Figure S3. TET1 binds to miR-191 in HCC cells. Figure S4. Forced or reduced TET1 expression in HCC cells. Figure S5. TET1 regulated the progression of HCC cells in vitro. Figure S6. circTRIM33–12 and TET1 regulate the expression of several same genes in HCC cells. (DOCX 3576 kb)

Published
2019
Full Text
View/download PDF

47. Additional file 4: of Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma

Author

Peng, Rui, Zhang, Peng-Fei, Yang, Xuan, Chuan-Yuan Wei, Huang, Xiao-Yong, Cai, Jia-Bin, Lu, Jia-Cheng, Gao, Chao, Sun, Hai-Xiang, Gao, Qiang, Dou-Sheng Bai, Shi, Guo-Ming, Ke, Ai-Wu, and Fan, Jia

Abstract

Figure S2. Confocal microscopy images of RNF38 and AHNAK. Shown are HCCLM3-NC cells (blue, DAPI; green, RNF38; red, AHNAK). Scale: 2000 × . (PDF 113 kb)

Published
2019
Full Text
View/download PDF

48. Additional file 3: of Circular RNA circTRIM33â 12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression

Author

Zhang, Peng-Fei, Chuan-Yuan Wei, Huang, Xiao-Yong, Peng, Rui, Yang, Xuan, Lu, Jia-Cheng, Zhang, Chi, Gao, Chao, Cai, Jia-Bin, Gao, Ping-Ting, Gao, Dong-Mei, Shi, Guo-Ming, Ke, Ai-Wu, and Fan, Jia

Subjects
endocrine system, endocrine system diseases, nutritional and metabolic diseases, digestive system, hormones, hormone substitutes, and hormone antagonists
Abstract

Table S2. Antibody for western blotting, immunofluorescence, RIP, and immunohistochemistry. (DOCX 17 kb)

Published
2019
Full Text
View/download PDF

50. Additional file 6: of Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma

Author

Peng, Rui, Zhang, Peng-Fei, Yang, Xuan, Chuan-Yuan Wei, Huang, Xiao-Yong, Cai, Jia-Bin, Lu, Jia-Cheng, Gao, Chao, Sun, Hai-Xiang, Gao, Qiang, Dou-Sheng Bai, Shi, Guo-Ming, Ke, Ai-Wu, and Fan, Jia

Abstract

Figure S4. Clinical relevance of RNF38 and/or AHNAK expression. A. The correlation between RNF38 and AHNAK were assessed by the Pearson correlation. B. RNF38 and AHNAK IOD relative value of 102 patients had negative correlation. C. HCC patients with low AHNAK had the lowest survival rate and the highest recurrence rate. D. HCC patients with high RNF38 and low AHNAK had the most unfavorable prognosis including the OS and recurrence. Group 1, patients of RNF38 low and AHNAK high (n = 30). Group 2, patients of both RNF38 and AHNAK low or high (n = 36), Group 3, patients of RNF38 high and AHNAK low (n = 36). (PDF 132 kb)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results